NCT06172322 2024-04-23
A Phase Ib/â…¡ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1 Unknown
Clinical Trials
40 trialsNCT06047184 2023-09-21
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
BeBetter Med Inc
Phase 1 Unknown
NCT05433480 2023-07-27
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT05806671 2023-04-10
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05792410 2023-03-31
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT03772353 2023-03-07
PLEASURABLE
Fudan University
Phase 1/2 Unknown
NCT02983071 2023-02-15
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
G1 Therapeutics, Inc.
Phase 1/2 Unknown
NCT05411380 2022-11-04
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Phase 2 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT05186545 2022-09-02
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05504213 2022-08-17
A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT02626507 2022-02-09
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Hoffman Oncology
Phase 1 Unknown
NCT03633331 2021-10-15
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT05076695 2021-10-13
NeoTPPF
Fudan University
Phase 2 Unknown
NCT05047848 2021-09-17
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
Liaoning Cancer Hospital & Institute
Phase NA Unknown
NCT04936295 2021-06-23
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04856371 2021-04-23
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT04796623 2021-03-15
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04753177 2021-02-15
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Phase 2/3 Unknown
NCT04034589 2020-12-22
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04355520 2020-04-21
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT02690480 2020-02-05
FLIPPER
Spanish Breast Cancer Research Group
Phase 2 Unknown
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT04033172 2019-07-25
Pyrotinib
ChineseAMS
Phase 2 Unknown
NCT00006903 2019-03-20
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
GOG Foundation
Phase 2 Unknown
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT03591549 2018-07-23
Fulvestrant in Metastatic Breast Cancer
Assiut University
Phase 4 Unknown
NCT02000193 2018-07-10
FANCY
Sun Yat-sen University
Phase 2 Unknown
NCT03560856 2018-06-18
PALPETBIO
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03202862 2017-06-29
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Fudan University
Phase 2 Unknown
NCT01266213 2017-05-01
FLAG
Samsung Medical Center
Phase 2 Unknown
NCT02646735 2017-01-02
FRIEND
ChineseAMS
Phase 2 Unknown
NCT02383030 2016-06-15
FUMANCE
Consorzio Oncotech
Phase 3 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT02072512 2014-02-26
PROOF
Hospital Affiliated to Military Medical Science, Beijing
Phase 2 Unknown
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00927511 2011-07-22
FIDeS
Regina Elena Cancer Institute
Phase 2 Unknown